View ValuationPharmigene 将来の成長Future 基準チェック /06現在、 Pharmigeneの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長35.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • Mar 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 4 independent directors (6 non-independent directors). Director Junyi Li was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Jan 30Pharmigene, Inc., Annual General Meeting, Jun 15, 2026Pharmigene, Inc., Annual General Meeting, Jun 15, 2026. Location: 3 floor no,302, chien kuo 1st rd., sinjhuang district, new taipei city TaiwanNew Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$86m free cash flow). Earnings have declined by 35% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Revenue is less than US$5m (NT$149m revenue, or US$4.9m). Market cap is less than US$100m (NT$570.3m market cap, or US$18.8m).Reported Earnings • Aug 15First half 2025 earnings released: NT$0.82 loss per share (vs NT$0.96 loss in 1H 2024)First half 2025 results: NT$0.82 loss per share (improved from NT$0.96 loss in 1H 2024). Revenue: NT$80.7m (up 68% from 1H 2024). Net loss: NT$41.3m (loss narrowed 15% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Board Change • Jun 23Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). Director Junyi Li was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 19Full year 2024 earnings released: NT$1.64 loss per share (vs NT$1.60 loss in FY 2023)Full year 2024 results: NT$1.64 loss per share (further deteriorated from NT$1.60 loss in FY 2023). Revenue: NT$116.5m (down 12% from FY 2023). Net loss: NT$82.9m (loss widened 14% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.お知らせ • Mar 12Pharmigene, Inc., Annual General Meeting, Jun 03, 2025Pharmigene, Inc., Annual General Meeting, Jun 03, 2025. Location: 3 floor no,302, chien kuo 1st rd., sinjhuang district, new taipei city TaiwanNew Risk • Feb 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$143m free cash flow). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (NT$127m revenue, or US$3.9m). Market cap is less than US$100m (NT$683.8m market cap, or US$20.8m).Reported Earnings • Aug 18First half 2024 earnings released: NT$0.96 loss per share (vs NT$0.66 loss in 1H 2023)First half 2024 results: NT$0.96 loss per share (further deteriorated from NT$0.66 loss in 1H 2023). Revenue: NT$47.9m (down 11% from 1H 2023). Net loss: NT$48.7m (loss widened 70% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Reported Earnings • May 04Full year 2023 earnings released: NT$1.60 loss per share (vs NT$0.98 loss in FY 2022)Full year 2023 results: NT$1.60 loss per share (further deteriorated from NT$0.98 loss in FY 2022). Revenue: NT$132.7m (flat on FY 2022). Net loss: NT$72.6m (loss widened 70% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • Apr 12Pharmigene, Inc., Annual General Meeting, Jun 24, 2024Pharmigene, Inc., Annual General Meeting, Jun 24, 2024.New Risk • Feb 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$132m revenue, or US$4.2m). Market cap is less than US$100m (NT$1.03b market cap, or US$32.6m).New Risk • Oct 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$132m revenue, or US$4.1m). Market cap is less than US$100m (NT$1.16b market cap, or US$35.9m).Reported Earnings • Aug 14First half 2023 earnings released: NT$0.66 loss per share (vs NT$0.53 loss in 1H 2022)First half 2023 results: NT$0.66 loss per share (further deteriorated from NT$0.53 loss in 1H 2022). Revenue: NT$53.6m (down 2.7% from 1H 2022). Net loss: NT$28.7m (loss widened 25% from 1H 2022).New Risk • Aug 09New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$681m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$132m revenue, or US$4.2m). Market cap is less than US$100m (NT$1.06b market cap, or US$33.4m).Reported Earnings • Apr 07Full year 2022 earnings released: NT$0.98 loss per share (vs NT$0.54 loss in FY 2021)Full year 2022 results: NT$0.98 loss per share (further deteriorated from NT$0.54 loss in FY 2021). Revenue: NT$133.8m (up 3.4% from FY 2021). Net loss: NT$42.7m (loss widened 82% from FY 2021).Reported Earnings • Apr 12Full year 2021 earnings released: NT$0.54 loss per share (vs NT$0.33 loss in FY 2020)Full year 2021 results: NT$0.54 loss per share (down from NT$0.33 loss in FY 2020). Revenue: NT$129.4m (up 28% from FY 2020). Net loss: NT$23.4m (loss widened 109% from FY 2020). このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Pharmigene は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:7595 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025200-73-76-67N/A9/30/2025175-74-81-56N/A6/30/2025149-76-86-45N/A3/31/2025133-79-99-45N/A12/31/2024117-83-112-45N/A9/30/2024122-88-127-68N/A6/30/2024127-93-143-92N/A3/31/2024130-83-444-85N/A12/31/2023133-73-745-78N/A9/30/2023133-61-713-52N/A6/30/2023132-48-681-27N/A3/31/2023133-46-358-25N/A12/31/2022134-43-34-23N/A9/30/2022129-40-38-24N/A6/30/2022125-37-42-24N/A3/31/2022127-30-40-22N/A12/31/2021129-23-38-19N/A9/30/2021120-20-32-16N/A6/30/2021110-16-26-12N/A3/31/2021106-13-24-12N/A12/31/2020101-11-22-13N/A9/30/202097-19-23-17N/A6/30/202092-27-24-21N/A3/31/202079-31-25-22N/A12/31/201965-35-25-24N/A12/31/201878-13N/A-5N/A12/31/201755-8N/A-18N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 7595の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 7595の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 7595の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 7595の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 7595の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 7595の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 23:22終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharmigene, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • Mar 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 4 independent directors (6 non-independent directors). Director Junyi Li was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Jan 30Pharmigene, Inc., Annual General Meeting, Jun 15, 2026Pharmigene, Inc., Annual General Meeting, Jun 15, 2026. Location: 3 floor no,302, chien kuo 1st rd., sinjhuang district, new taipei city Taiwan
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$86m free cash flow). Earnings have declined by 35% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Revenue is less than US$5m (NT$149m revenue, or US$4.9m). Market cap is less than US$100m (NT$570.3m market cap, or US$18.8m).
Reported Earnings • Aug 15First half 2025 earnings released: NT$0.82 loss per share (vs NT$0.96 loss in 1H 2024)First half 2025 results: NT$0.82 loss per share (improved from NT$0.96 loss in 1H 2024). Revenue: NT$80.7m (up 68% from 1H 2024). Net loss: NT$41.3m (loss narrowed 15% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Board Change • Jun 23Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). Director Junyi Li was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 19Full year 2024 earnings released: NT$1.64 loss per share (vs NT$1.60 loss in FY 2023)Full year 2024 results: NT$1.64 loss per share (further deteriorated from NT$1.60 loss in FY 2023). Revenue: NT$116.5m (down 12% from FY 2023). Net loss: NT$82.9m (loss widened 14% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 12Pharmigene, Inc., Annual General Meeting, Jun 03, 2025Pharmigene, Inc., Annual General Meeting, Jun 03, 2025. Location: 3 floor no,302, chien kuo 1st rd., sinjhuang district, new taipei city Taiwan
New Risk • Feb 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$143m free cash flow). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (NT$127m revenue, or US$3.9m). Market cap is less than US$100m (NT$683.8m market cap, or US$20.8m).
Reported Earnings • Aug 18First half 2024 earnings released: NT$0.96 loss per share (vs NT$0.66 loss in 1H 2023)First half 2024 results: NT$0.96 loss per share (further deteriorated from NT$0.66 loss in 1H 2023). Revenue: NT$47.9m (down 11% from 1H 2023). Net loss: NT$48.7m (loss widened 70% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 04Full year 2023 earnings released: NT$1.60 loss per share (vs NT$0.98 loss in FY 2022)Full year 2023 results: NT$1.60 loss per share (further deteriorated from NT$0.98 loss in FY 2022). Revenue: NT$132.7m (flat on FY 2022). Net loss: NT$72.6m (loss widened 70% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 12Pharmigene, Inc., Annual General Meeting, Jun 24, 2024Pharmigene, Inc., Annual General Meeting, Jun 24, 2024.
New Risk • Feb 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$132m revenue, or US$4.2m). Market cap is less than US$100m (NT$1.03b market cap, or US$32.6m).
New Risk • Oct 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$132m revenue, or US$4.1m). Market cap is less than US$100m (NT$1.16b market cap, or US$35.9m).
Reported Earnings • Aug 14First half 2023 earnings released: NT$0.66 loss per share (vs NT$0.53 loss in 1H 2022)First half 2023 results: NT$0.66 loss per share (further deteriorated from NT$0.53 loss in 1H 2022). Revenue: NT$53.6m (down 2.7% from 1H 2022). Net loss: NT$28.7m (loss widened 25% from 1H 2022).
New Risk • Aug 09New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$681m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$681m free cash flow). Earnings have declined by 23% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$132m revenue, or US$4.2m). Market cap is less than US$100m (NT$1.06b market cap, or US$33.4m).
Reported Earnings • Apr 07Full year 2022 earnings released: NT$0.98 loss per share (vs NT$0.54 loss in FY 2021)Full year 2022 results: NT$0.98 loss per share (further deteriorated from NT$0.54 loss in FY 2021). Revenue: NT$133.8m (up 3.4% from FY 2021). Net loss: NT$42.7m (loss widened 82% from FY 2021).
Reported Earnings • Apr 12Full year 2021 earnings released: NT$0.54 loss per share (vs NT$0.33 loss in FY 2020)Full year 2021 results: NT$0.54 loss per share (down from NT$0.33 loss in FY 2020). Revenue: NT$129.4m (up 28% from FY 2020). Net loss: NT$23.4m (loss widened 109% from FY 2020).